Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Laggard
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
.
(
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.7%. By the end of trading, Vertex Pharmaceuticals fell 45 cents (-1.1%) to $39.53 on average volume. Throughout the day, 2.2 million shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2.3 million shares. The stock ranged in price between $38.44-$39.65 after having opened the day at $38.94 as compared to the previous trading day's close of $39.98. Other companies within the Drugs industry that declined today were:
(
), down 14.8%,
(
), down 12.5%,
(
), down 10.3%, and
(
), down 8.9%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Vertex Pharmaceuticals has a market cap of $8.78 billion and is part of the health care sector. The company has a P/E ratio of 65.3, above the S&P 500 P/E ratio of 17.7. Shares are up 22% year to date as of the close of trading on Tuesday. Currently there are 14 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and three rate it a hold.
TheStreet Ratings rates Vertex Pharmaceuticals as a
. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share.
- You can view the full Vertex Ratings Report.
On the positive front,
(
), up 39.5%,
(
), up 20.2%,
(
), up 17.9%, and
(
), up 17.3%, were all gainers within the drugs industry with
(
) being today's featured drugs industry leader.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade
.
null